Abstract Purpose: The 2-part, phase I/IIa, open-label study (NCT01677741) sought to
determine the safety, tolerability, pharmacokinetics, and preliminary activity of dabrafenib in …

Purpose: Pediatric low-grade glioma (pLGG) is the most prevalent childhood brain tumor.
Patients with BRAF V600 mutation–positive pLGG may benefit from treatment with …

10004 Background: Dabrafenib is an orally available, selective ATP-competitive inhibitor of
BRAF V600E kinase, approved in unresectable or metastatic melanoma pts with the V600E …

The recent US Food and Drug Administration (FDA) approval of the dabrafenib/trametinib
combination as a tissue-agnostic treatment for solid tumors with BRAF V600E mutation is the …

PURPOSE BRAFV600 mutations are commonly found in melanoma and thyroid cancers
and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH …

Purpose: Dabrafenib is a selective, potent ATP-competitive inhibitor of the BRAF V600-
mutant kinase that has demonstrated efficacy in clinical trials. We report the rationale for …

BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …

Dabrafenib is an orally bioavailable, potent, and selective inhibitor of human wild‐type
BRAF and CRAF kinases as well as mutant forms of BRAF kinase. The aim of this phase 1 …

BRAF V600E mutations have been successfully treated with targeted therapy in melanoma,
non–small cell lung cancer, and thyroid cancer. Interestingly, these mutations have also …

Dabrafenib (Tafinlar®), a mutant-BRAF kinase inhibitor, emerged from GlaxoSmithKline's
research programme for the discovery of selective inhibitors of mutant BRAF kinase activity …